U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C18H24I3N3O8
Molecular Weight 791.1119
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOXILAN

SMILES

CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I

InChI

InChIKey=UUMLTINZBQPNGF-UHFFFAOYSA-N
InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

HIDE SMILES / InChI

Description

Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Iodinated contrast agents may cross the blood-brain barrier.

Originator

Approval Year

1995
203
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8583
OXILAN-300

Approved Use

INTRAARTERIAL: OXILAN® Injection (300 mgI/mL) is indicated for cerebral arteriography. OXILAN® Injection (350 mgI/mL) is indicated for coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography. INTRAVENOUS: OXILAN® Injection (300 mgI/mL) and OXILAN® Injection (350 mgI/mL) are indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body.

Launch Date

1995
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.5 min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.1 min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
100%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34266
https://www.001chemical.com/chem/107793-72-6
Alfa Chemistry
AP107793726
https://reagents.alfa-chemistry.com/product/ioxilan-cas-107793-72-6-1366.html
Ambinter
Amb22055548
http://www.ambinter.com/reference/22055548
Avantor Inc
101095-240
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-240
Avantor Inc
101097-070
https://us.vwr.com/store/catalog/product.jsp?catalog_number=101097-070
BioSynth
J-002011
https://www.biosynth.com/en/products/all-products/products/J-002011.html
BLD Pharm
BD134822
http://www.bldpharm.com/products/107793-72-6.html
Boerchem
BC678009
http://www.boerchem.com/?product_39658.html
Chem Scene
CS-0031230
http://www.chemscene.com/107793-72-6.html
ChemMol
44010108
http://www.chemmol.com/chemmol/44010108.html
Chemspace
CSSS00020617586
https://chem-space.com/CSSS00020617586
Finetech
FT-0627286
http://www.finetechnology-ind.com/prod/detail/pub/107793-72-6.html
Glentham Life Sciences
GP6623
http://www.glentham.com/products/product/GP6623/
MedChem Express
HY-109513
https://www.medchemexpress.com/ioxilan.html
Molcore
MC34266
https://www.molcore.com/product/107793-72-6
MolPort
MolPort-027-948-870
https://www.molport.com/shop/molecule-link/MolPort-027-948-870
Smolecule
S576412
https://www.smolecule.com/products/s576412
THE BioTek
bt-370899
https://www.thebiotek.com/product/others/bt-370899
Yuhao Chemical
RT1900
http://www.chemyuhao.com/107793-72-6.html
PubMed

PubMed

TitleDatePubMed
Dimethyl 5-amino-2,4,6-triiodo-isophthalate.
2010-01-16
Contrast-induced nephropathy morbidity and mortality following percutaneous coronary intervention.
2009-12-15
Contrast induced nephropathy in urology.
2009-12-04
Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
2009-06-15
Ethyl 3-carb-oxy-5-nitro-benzoate.
2009-04-30
Methyl 3-carboxy-5-nitrobenzoate.
2009-01-17
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
2008-09-03
Risk of thrombogenicity among nonionic radiocontrast agents.
2008-07
A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.
2007-11-14
Transient interruption of contrast on CT pulmonary angiography: proof of mechanism.
2007-05
Adrenocortical carcinoma: contrast washout characteristics on CT.
2006-07
Quantitation of regional cerebral blood flow: the next chapter in digital subtraction angiography.
2006-04
Comparison of asymmetry in cerebral blood flow between brain hemispheres using digital subtraction angiography.
2006-04
Decrease in fluoroscopic cardiac silhouette excursion precedes hemodynamic compromise in intraprocedural tamponade.
2005-11
Polyp size at CT colonography after electronic subtraction cleansing in an anthropomorphic colon phantom.
2005-07
Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials.
2005-07
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on acid base, blood gas and electrolyte status in dogs.
2004-06
Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
2003-12
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on coagulation times and some blood parameters in dogs: an in vivo study.
2003-08
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].
2003-05-02
Reactions to radiocontrast media.
2002-12-13
[A state of delirium (confusion) following cerebral angiography with ioxilan: a case report].
2002-06
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?
2001-12
Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration.
2001-05
Effects of nonionic contrast media on platelet aggregation: assessment by particle counting with laser-light scattering.
2001-01
Patents

Patents

JP2007529285A
16

Sample Use Guides

In Vivo Use Guide
300 mgI/mL or 350 mgI/mL injection
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
IOXILAN
INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OXILAN-300
Preferred Name English
N-(2,3-DIHYDROXYPROPYL)-5-(N-(2,3-DIHYDROXYPROPYL)ACETAMIDO)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODOISOPHTHALAMIDE
Systematic Name English
IOXILAN [MI]
Common Name English
IOXILAN [JAN]
Common Name English
OXILAN
Brand Name English
IOXILAN [USP MONOGRAPH]
Common Name English
IOXILAN [USAN]
Common Name English
1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N-(2,3-DIHYDROXYPROPYL)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODO-
Systematic Name English
IOXILAN [USP IMPURITY]
Common Name English
ioxilan [INN]
Common Name English
IOXILAN [VANDF]
Common Name English
NSC-760056
Code English
Ioxilan [WHO-DD]
Common Name English
IOXILAN [MART.]
Common Name English
LOXILAN [VANDF]
Common Name English
IOXITOL
Common Name English
IOXILAN [USP-RS]
Common Name English
IOXILAN [ORANGE BOOK]
Common Name English
1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N1-(2,3-DIHYDROXYPROPYL)-N3-(2-HYDROXYETHYL)-2,4,6-TRIIODO-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QV08AB12
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
NCI_THESAURUS C28500
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
NDF-RT N0000010258
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
NDF-RT N0000180185
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
WHO-ATC V08AB12
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
Code System Code Type Description
PUBCHEM
3743
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
CAS
107793-72-6
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
USAN
Z-32
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
SMS_ID
100000083136
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
DRUG BANK
DB09135
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
EVMPD
SUB08265MIG
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
NCI_THESAURUS
C65948
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201075
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
MESH
C055357
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
NSC
760056
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
FDA UNII
A4YJ7J11TG
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
MERCK INDEX
m6381
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY Merck Index
LACTMED
Ioxilan
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
RS_ITEM_NUM
1345206
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
INN
6301
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
WIKIPEDIA
Ioxilan
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
DRUG CENTRAL
1473
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
EPA CompTox
DTXSID0048717
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY
RXCUI
27793
Created by admin on Mon Mar 31 18:27:47 GMT 2025 , Edited by admin on Mon Mar 31 18:27:47 GMT 2025
PRIMARY RxNorm
ACTIVE MOIETY
Structure of IOXILAN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966